Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.86+1.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RCKT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||
| Revenues | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Operating Expenses & Income | ||||||||||||
| R&D Expenses | 124.4 | 142.0 | 171.2 | 186.3 | 165.6 | 125.5 | 105.4 | 57.9 | 53.3 | 14.9 | 6.0 | 12.6 |
| Operating Income | (191.6) | (231.7) | (273.2) | (259.7) | (224.3) | (167.2) | (134.3) | (76.2) | (71.2) | (19.8) | (7.6) | (20.4) |
| Earnings from Continuing Operations | ||||||||||||
| Interest Expense | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 3.0 | 7.0 | 6.0 | 6.0 | 0.0 | 0.0 | 1.2 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | 0.8 | 0.4 | 0.1 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | (0.8) | (0.4) | 1.1 |
| Other Non-Operating Income / Expenses | — | — | — | — | 2.5 | (1.8) | (5.4) | — | — | — | — | — |
| Asset Writedown | — | — | — | — | — | — | — | — | — | 0.4 | — | — |
| EBT, Incl. Unusual Items | — | (223.1) | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | — | — | — | — | — | — | — | — |
| Net Income | ||||||||||||
| Net Income | (17.3) | (223.1) | (258.7) | (245.6) | (221.9) | (169.1) | (139.7) | (77.3) | (74.5) | (19.6) | (7.6) | (68.0) |
| Per Share | ||||||||||||
| Basic EPS | (0.15) | (2.01) | (2.73) | (2.92) | (3.26) | (2.67) | (2.52) | — | — | — | — | — |
| Diluted EPS | (0.15) | (2.01) | (2.73) | (2.92) | (3.26) | (2.67) | (2.52) | — | — | — | — | — |
| Basic Weighted Avg Shares | 112.8 | 111.1 | 94.8 | 84.0 | 68.1 | 63.2 | 55.4 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 114.5 | 111.1 | 94.8 | 84.0 | 68.1 | 63.2 | 55.4 | — | — | — | — | — |
| Supplemental | ||||||||||||
| EBITDA | — | (222.8) | (266.0) | (254.8) | (220.4) | (164.0) | (133.2) | — | — | — | — | — |
| EBIT | (191.6) | (231.7) | (273.2) | (259.7) | (224.3) | (167.2) | (134.3) | (76.2) | (71.2) | (19.8) | (7.6) | (20.4) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.